instruction:
Given a document, an entity and its sentiment towards the entity, verify if it is the correct sentiment towards the entity. Answer should be yes or no. Note that URLs in the text have been replaced with [Link].
question:
Verify if the sentiment of the following document towards the entity Elizabeth Warren is Neutral . President Trump revived his favorite insult for Sen. Elizabeth Warren (D-MA) during a speech at a Navajo Code Talkers event at the White House Monday. Here's how he brought up the "Pocahontas" insult - context and all.
"I just want to thank you because you're very  very special people " Trump said to his guests. "You were here long before any of us were here  although we have a representative in Congress who  they say  was here a long time ago. They call her [ Elizabeth Warren ] 'Pocahontas '" he said. "But you know what  I like you because you are special. You are special people. You are really incredible people. And from the heart  from the absolute heart  we appreciate what you've done  how you've done it  the bravery that you displayed  and the love that you have for your country."
The senator was not amused.  Warren  told MSNBC  she  was shocked that the president had used a "racial slur" at a ceremony intended to honor Native American war heroes.
 She  then used the incident to fundraise.
 Elizabeth Warren   in an email to supporters  is fundraising off Donald Trump’s Pocahontas comment pic.twitter.com/11Xb27RS8D — Dan Merica (@danmericaCNN) November 28  2017
As Katie noted  the press is missing the point. Instead of being outraged over President Trump's insults  why not call out  Sen. Warren  for shamefully faking  her  heritage to game the affirmative action system?
In 2012   Warren  reportedly touted  her  "Native American heritage" ( she 's 1/32nd Cherokee) to convince the Harvard Law School faculty  she 'd increase the school's diversity.  She  has denied those claims  noting that  she  listed  herself  as Native American to meet others like  herself   according to The Chronicle of Higher Education.
answer:
no


question:
Verify if the sentiment of the following document towards the entity Jas Boothe is Negative . And there's one more story from the White House we want to focus on now. Earlier in the week  we learned that the president has asked the Pentagon to look into staging a military parade. It seems intended as a celebration of the military and a demonstration of military might. So we thought  who better to ask about this than the people who served in uniform and whose service is being honored? And where better to talk about this than in the Barbershop  because that's where we talk to interesting folks about what's in the news and what's on their mind? So joining us today is  Jas Boothe .  She  served for 16 years in the Army and the Army Reserves.  She  served in Kosovo  among other assignments. As  she  prepared to deploy for Operation Iraqi Freedom  though   she  was diagnosed with cancer.  She  was eventually discharged. And  she  now runs Final Salute Inc. That's an organization that helps homeless women veterans  as  she  once was.  She 's also the mother of a son serving in the Air Force and is the wife of a former Marine. Major  thank you so much for speaking with us.
PLENZLER: Yeah  I have concerns mostly around the intent and the impact of the event  plus the cost. I agree with  Jas  on that. And  you know  our national military culture  we have parades where we roll out the active duty when it's a victory parade. And the war in Afghanistan is still going on. And the war in Iraq and Syria is still going on. So  I mean  we're nowhere near the end of those two conflicts. And it may go on for some years now.
MARTIN: And what about that   Jas ? I mean  one of the things that was striking to me is that a number of the people talking about this  particularly some of the millennial era - millenniums  millennials  rather - who have been - who are very active on social media  and one of their arguments was that this kind of conjures up the image of authoritarian  you know  governments like  you know  North Korea. You know  obviously  North Korea  that these huge displays of might are kind of a signature - Venezuela  Russia. I'm going to ask you the same thing - what Sherman's point is. What if - what about something that says  I respect and appreciate you?
MARTIN: OK. Well  as we get closer  we'll call you back and see how you all feel then. That's Sherman Gillums Jr.  Marine veteran  chief strategy officer for American Veterans  AMVETS. Joe Plenzler  another Marine veteran  director of media for The American Legion. Jas Boothe  former veteran  founder of Final Salute. We want to emphasize they're all speaking for themselves. But thank you all so much for coming. And  if I may - and I understand it's controversial - thank you for your service.
answer:
no


question:
Verify if the sentiment of the following document towards the entity Kymriah is Positive . The drug  called  Kymriah   is a highly personalized cancer treatment called CAR T-cell therapy (CAR is short for chimeric antigen receptor).
The FDA approved  Kymriah  to treat pediatric acute lymphoblastic leukemia in people up to age 25.
The one-time treatment isn't cheap: Novartis  which makes  Kymriah   on Wednesday said the price would be $475 000  which is lower than many expected. Only about 600 people a year could get this treatment  based on Wednesday's approval. Even so  the approval has industry experts and cancer doctors excited.
How  Kymriah  works
 Kymriah  isn't your run-of-the-mill pill â or even a biologic drug  like insulin â that can be mass produced. Since the therapy is made from a person's own immune system  the process can take about three weeks.
While that's a one-time process  it's not the end of the road. About half of the patients in a Kymriah study got cytokine-release syndrome  a response to the reprogrammed cells running loose in the body. It can cause high fevers and flu-like symptoms  and it can be life-threatening. If they get it  patients need to be admitted to intensive-care units  which can bring additional costs. (The FDA on Wednesday expanded the approval of Actemra  a rheumatoid-arthritis drug that can also treat cytokine-release syndrome.)
In a trial of 63 patients treated with Kymriah  83% were in remission after three months  and 64% were still in remission after a year.
Kymriah is the first CAR-T cell therapy to get approved  and several more are in the works. Kite Pharma  Juno Therapeutics  and Bluebird Bio are among a growing group of biotech companies working with CAR-T. Kite  which was recently acquired by Gilead Sciences  is expected to hear back from the FDA about its treatment for aggressive B-cell non-Hodgkin lymphoma by November.
"We're at the very beginning of what's going to be a big new field of medicine " said  David Epstein  who helped license Kymriah from the University of Pennsylvania while at Novartis .
 Epstein  left Novartis in 2016 as CEO of its pharmaceuticals divisions.  He 's now the executive chairman of Rubius Therapeutics  a biotech firm that's also working with cell therapy to develop treatments like  Kymriah  that don't have to be as personalized. The hope is that one day doctors will be able to prescribe a cell therapy and use it that same day instead of waiting weeks to get it back.
 Epstein  said  he  envisioned cell therapies having much shorter life cycles than traditional drugs. Instead of getting a better  updated therapy for a disease every decade or so  we might begin to see second-generation cell therapies in a few years.
Those updates could increase the number of patients that cell therapies can treat. The 600 or so people a year eligible for  Kymriah  now could become tens of thousands  but  it  would require some major changes   Epstein  said.
For one  the treatments would have to treat more types of cancer than the one  Kymriah  was approved for on Wednesday.
And to affect more people  the cell therapies would need to go beyond blood cancers. Right now  that's where most of the big successes have come from  but that could one day include solid tumors and maybe even autoimmune diseases like Type 1 diabetes   Epstein  said.
answer:

yes